LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL

Stone JH, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony S (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 145-146

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

Event location: Madrid

DOI: 10.1136/annrheumdis-2019-eular.2099

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Genentech Inc.

United States (USA) (US) University of Groningen / Rijksuniversiteit Groningen

Netherlands (NL) Universitätsklinikum Carl Gustav Carus Dresden

Germany (DE) Harvard University

United States (USA) (US) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven

Belgium (BE) Arcispedale Santa Maria Nuova

Italy (IT) Southend Hospital

United Kingdom (GB) Hospital for Special Surgery (HSS)

United States (USA) (US) Universitat de Barcelona (UB) / University of Barcelona

Spain (ES)

How to cite

APA:

Stone, J.H., Bao, M., Han, J., Aringer, M., Blockmans, D., Brouwer, E.,... Unizony, S. (2019). LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL. In ANNALS OF THE RHEUMATIC DISEASES (pp. 145-146). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.

MLA:

Stone, John H., et al. "LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL." Proceedings of the Annual European Congress of Rheumatology (EULAR), Madrid LONDON: BMJ PUBLISHING GROUP, 2019. 145-146.

BibTeX: Download